Yes it seems like a good move.
My simplistic way of looking at things is if they can get up to $40m cash for low double digits bronchitol sales revenue for CF only, how much is the 85 to 89% of those sales worth? Then PXS also has aridol, hopeful bronchitol for bronchiectasis and the rest of the pipe line.
So lets hope Mr Phillips can open the eyes of investors to some of that potential.
notice received, page-8
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
